Text Size
71 studies found for:    "Salivary Gland Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Withdrawn Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Conditions: Adenoma, Pleomorphic;   Mixed Salivary Gland Tumor;   Salivary Gland Tumor, Mixed;   Syringoma, Chondroid
Interventions: Radiation: Radiation;   Drug: Panitumumab
2 Recruiting Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Conditions: Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
Intervention:
3 Recruiting A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Malignant Salivary Gland Tumors
Interventions: Drug: Cisplatin: 40 mg/m2 weekly during radiation;   Radiation: Radiation: 60-66 Gy in 2 Gy daily fractions
4 Completed Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Condition: Head and Neck Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: gemcitabine hydrochloride
5 Recruiting Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
6 Active, not recruiting Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer
Interventions: Drug: dasatinib;   Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: mutation analysis;   Genetic: allele-specific oligonucleotide real-time quantitative polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacogenomic studies
7 Completed Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Conditions: High-grade Salivary Gland Carcinoma;   High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
8 Active, not recruiting Iressa Study in Patients With Salivary Gland Cancer
Condition: Salivary Gland Cancer
Intervention: Drug: ZD1839 (Iressa)
9 Recruiting A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Conditions: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands;   Metastatic Adenoid Cystic Carcinoma of the Salivary Glands;   Salivary Gland Cancers;   ACC
Intervention: Drug: Dovitinib
10 Completed Phase III Randomized, Placebo Controlled, Trial Of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib, NSC 715055) In Performance Status 2 Or Previously Treated Patients With Recurrent Or Metastatic Head And Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: docetaxel;   Other: placebo;   Drug: gefitinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Terminated Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Poorly Differentiated Carcinoma;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
12 Completed L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
Conditions: Mucositis;   Oral Complications of Chemotherapy;   Oral Complications of Radiation Therapy;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Adenoid Cystic Carcinoma of the Oral Cavity;   Stage I Basal Cell Carcinoma of the Lip;   Stage I Lymphoepithelioma of the Nasopharynx;   Stage I Lymphoepithelioma of the Oropharynx;   Stage I Mucoepidermoid Carcinoma of the Oral Cavity;   Stage I Salivary Gland Cancer;   Stage I Squamous Cell Carcinoma of the Hypopharynx;   Stage I Squamous Cell Carcinoma of the Larynx;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Nasopharynx;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Larynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Adenoid Cystic Carcinoma of the Oral Cavity;   Stage II Basal Cell Carcinoma of the Lip;   Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Lymphoepithelioma of the Oropharynx;   Stage II Mucoepidermoid Carcinoma of the Oral Cavity;   Stage II Salivary Gland Cancer;   Stage II Squamous Cell Carcinoma of the Hypopharynx;   Stage II Squamous Cell Carcinoma of the Larynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Larynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Procedure: quality-of-life assessment;   Procedure: management of therapy complications;   Dietary Supplement: L-lysine
13 Terminated Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck
Conditions: Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Intervention: Biological: PV701
14 Completed S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
15 Recruiting Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: cisplatin;   Drug: docetaxel;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy
16 Completed Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
17 Not yet recruiting Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: afatinib;   Other: placebo;   Other: laboratory biomarker analysis
18 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Conditions: Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Tongue Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: fluorouracil;   Drug: hydroxyurea;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis
19 Active, not recruiting Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab;   Other: placebo;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
20 Completed Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Adenoid Cystic Carcinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Salivary Gland Cancer
Interventions: Drug: bortezomib;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years